15 January 2024 (Monday) - Fungal Infections


Here's something from the nice people at Lablogatory. Perhaps not of immediate relevance to me, but it made me think. I didn’t realise that fungal infections are so prevalent.
One lives and learns… by doing CPD

10 January 2024 (Wednesday) - IBMS Update

The IBMS sent out its monthly newsletter today. It had articles on the new president of the IBMS, a political joint statement with a commercial company pointing out all the problems the profession faces whilst offering no solutions, a plea for more portfolio verifiers (something for which I volunteered and have heard nothing)… 
The whole point of CPD is detailed here. I won’t dismiss the IBMS newsletter out of hand, but I will make the observation that more and more our professional body is catering to a smaller and smaller proportion of our profession.

Mind you as I’ve said before, the IBMS is like a dustbin; you only get out of it that which you put in. And having said that, am I wrong in thinking that putting in eighteen quid each month is quite enough?
(there’s reflection for you!)

4 January 2024 (Thursday) - Complete Failure at BTLP-TACT

 
I had decided not to bother with BTLP-TACT any more… I don’t so much mind getting it wrong as not knowing why I’ve got it wrong. As I tell the trainees, stuffing it up is how you learn. But you only learn *if* you find out where you went wrong. As a learning tool, BTLP-TACT leaves a *lot* to be desired.
But I had two goes…
 
On each occasion I was given no cases so I cannot have got it wrong… but both times it failed me for not doing that which wasn’t there to be done.





So what do I do now?

3 January 2024 (Wednesday) - Horiba Newsletter

The nice people at Horiba sent their morphology newsletter today. You can see it by clicking here.
This could be a useful resourse…

2 January 2024 (Tuesday) - Fritsma Factor Newsletter

The Fritsma Factor newsletter came out today. More and more I’m finding I’m forgetting so much about haemostasis. Back in the day we used to do so many more tests in-house. These days pretty much everything is referred out to specialist centres. Such a shame. But thre Fritsma Factor newsletter reminds me of that which I would otherwise forget…

27 December 2023 (Wednesday) - 2306 DM


The results of NEQAS 2306 DM are out.
“A 60 year-old female who is known to have hepatic cirrhosis becomes acutely unwell with a new anaemia (Hb 78 g/l). Associated with her hepatic cirrhosis she has a long-standing moderate thrombocytopenia. The clinicians are concerned about bleeding. What do you report?”
 
I saw burr cells, target cells, spherocytes, polychromasia, red cell fragments, acanthocytes, nucleated red cells, neutrophilia and a reduced platelet count. I felt this was a haemolytic process.
 
It was actually “spur cell anaemia”; something of which no one has ever heard. On the one hand you have to ask the benefit of giving us something so obscure for an EQA. On the other hand, here’s something for me to go and find out about.

22 December 2023 (Friday) - Stem Cell Evidence Alert

The Stem Cell Evidence Alert update arrived in my in-box today. There was quite a bit of talk about allogenic stem cell transplants. Back in the day we used to do quite a few of those… but they don’t seem to be anywhere near as common these days.
Perhaps it is a “specialist centre” thing and not something done is the district general hospitals any more?
 

ARTICLE OF THE MONTH

Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA.Jodele, S., et al. (2023) Blood [record in progress]PICO SUMMARY

+++++

TOP ARTICLES

Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry.Abadir, E., et al. (2023) Transplantation and Cellular Therapy [record in progress]

Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis.Chichra, A., et al. (2023) International Journal of Hematology [record in progress].Reconstitution of Natural Killer cells after allogeneic hematopoietic stem cell transplantation is facilitated by Huiyang-Guben decoction through activating the Smad7/Stat3 signal pathway.Gao, X., et al. (2023) Molecular and Cellular Biochemistry [record in progress]

Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study.Gerbitz, A., et al. (2023) Frontiers in Immunology 14:1251593

Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.Harbi, S., et al. (2023) Bone Marrow Transplantation [record in progress]

Chronic graft-versus-host disease is characterized by high levels and distinctive tissue-of-origin patterns of cell-free DNA.Pang, Y., et al. (2023) iScience 26:108160

Assessment of monocytic-myeloid-derived suppressive cells (M-MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients.Peterlin, P., et al. (2023) EJHaem 4 (4):1089-1095

Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease.Strobl, J., et al. (2023) The British Journal of Dermatology [record in progress]

Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.Yang, L., et al. (2023) Bone Marrow Transplantation [record in progress]

+++++